If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password
If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password
Barry Maron (Figure 1) was born in Los Angeles, California, on 22 August 1941, and he grew up there. After
public high school, he went to Occidental College in Los Angeles, graduating in 1963,
and then he went to New Orleans, Louisiana, to Tulane University School of Medicine,
where he graduated in 1968. His internship was in pediatrics at University Hospitals,
University of Wisconsin, in Madison, and his 1-year residency in pediatrics was at
Stanford University Medical Center in Palo Alto, California. His 2-year fellowship
in pediatric cardiology was at The Johns Hopkins Hospital, where he finished in 1972.
He then went to the National Heart Institute (later called National Heart, Lung, and
Blood Institute) as a staff associate and senior investigator in the cardiology branch
in Bethesda, Maryland, and he remained at the National Institutes of Health for 21
years, leaving in 1993 to become director of the cardiovascular research division
and hypertrophic cardiomyopathy center of the Minneapolis Heart Institute Foundation
in Minneapolis, Minnesota. During these last 30+ years, Barry Maron has been a world
class investigator in clinical cardiology. His focus has been primarily on clinical
aspects of hypertrophic cardiomyopathy, but he has done much work also in the area
of sudden death in athletes and young people. His investigations have led to the publication
of over 650 articles, mainly in peer review medical journals, including 23 publications
in the New England Journal of Medicine (10 in the Journal of the American Medical Association and 100 in Circulation.) Dr. Maron has been a friend and colleague for >30 years. He and his wonderful wife
are the parents of 2 sons, both of whom are physicians and on the path also to be
major cardiovascular investigators. It was a pleasure to spend the time talking to
Dr. Maron.
Figure 1Photograph of Dr. Maron during the interview.
Differences in distribution of myocardial abnormalities in patients with obstructive and nonobstructive asymmetric septal hypertrophy (ASH): light and electron microscopic findings.
Patterns and significance of the distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a wide-angle, two-dimensional echocardiographic study of 125 patients.
Hypertrophic cardiomyopathy with unusual locations of left ventricular hypertrophy undetectable by M-mode echocardiography: identification by wide-angle, two-dimensional echocardiography.
Systolic anterior motion of the posterior mitral leaflet: a previously unrecognized cause of dynamic subaortic obstruction in hypertrophic cardiomyopathy.
Anomalous insertion of papillary muscle directly into anterior mitral leaflet in hypertrophic cardiomyopathy: significance in producing left ventricular outflow obstruction.
Cardiac disease in young trained athletes: insights into methods for distinguishing athlete’s heart from structural heart disease with particular emphasis on hypertrophic cardiomyopathy.
Assessment of the prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA Study.
Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy::Morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients.
Cardiovascular preparticipation screening of competitive athletes: a statement for Health Professionals from the Sudden Death Committee (Clinical Cardiology) and Congenital Cardiac Defects Committee (Cardiovascular Diseases in the Young) American Heart Association.
Pitfalls in clinical recognition and a novel operative approach for hypertrophic cardiomyopathy with severe outflow obstruction due to anomalous papillary muscle.
Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy: a randomized, double-blind cross-over study (M-PATHY).
